BACKGROUND: Lung transplant recipients (LTR) have an increased risk of cutaneous squamous cell carcinoma (SCC) due to immunosuppressive therapy. Voriconazole, which is associated with phototoxic side effects in some patients, may be an additional risk factor for SCC in this population. METHODS: To test whether voriconazole is a risk factor for developing SCC in LTR, we evaluated cumulative exposure to voriconazole in 327 adults who underwent lung transplantation at one center between 1991 and 2010. Voriconazole exposure was assessed as a time-varying covariate. We used survival analysis methods to assess the risk of developing SCC over time. RESULTS: Exposure to voriconazole was associated with a 2.6-fold increased risk for SCC. This phenomenon was dose-dependent: the risk for SCC increased by 5.6% with each 60-day exposure at a standard dose of 200 mg twice daily. At 5 years after transplant, voriconazole conferred an absolute risk increase for SCC of 28%. CONCLUSIONS: These results suggest that caution should be taken when using voriconazole in LTR because this drug increases the already high risk for SCC in this population.
BACKGROUND: Lung transplant recipients (LTR) have an increased risk of cutaneous squamous cell carcinoma (SCC) due to immunosuppressive therapy. Voriconazole, which is associated with phototoxic side effects in some patients, may be an additional risk factor for SCC in this population. METHODS: To test whether voriconazole is a risk factor for developing SCC in LTR, we evaluated cumulative exposure to voriconazole in 327 adults who underwent lung transplantation at one center between 1991 and 2010. Voriconazole exposure was assessed as a time-varying covariate. We used survival analysis methods to assess the risk of developing SCC over time. RESULTS: Exposure to voriconazole was associated with a 2.6-fold increased risk for SCC. This phenomenon was dose-dependent: the risk for SCC increased by 5.6% with each 60-day exposure at a standard dose of 200 mg twice daily. At 5 years after transplant, voriconazole conferred an absolute risk increase for SCC of 28%. CONCLUSIONS: These results suggest that caution should be taken when using voriconazole in LTR because this drug increases the already high risk for SCC in this population.
Authors: L Naldi; A B Fortina; S Lovati; A Barba; E Gotti; G Tessari; D Schena; A Diociaiuti; G Nanni; I L La Parola; C Masini; S Piaserico; A Peserico; T Cainelli; G Remuzzi Journal: Transplantation Date: 2000-11-27 Impact factor: 4.939
Authors: Robert P Carroll; Helen M Ramsay; Anthony A Fryer; Carmel M Hawley; David L Nicol; Paul N Harden Journal: Am J Kidney Dis Date: 2003-03 Impact factor: 8.860
Authors: M Mansh; M Binstock; K Williams; F Hafeez; J Kim; D Glidden; R Boettger; S Hays; J Kukreja; J Golden; M M Asgari; P Chin-Hong; J P Singer; S T Arron Journal: Am J Transplant Date: 2015-09-03 Impact factor: 8.086
Authors: Christopher Metchnikoff; Thaddeus Mully; Jonathan P Singer; Jeffrey A Golden; Sarah T Arron Journal: J Am Acad Dermatol Date: 2012-01-29 Impact factor: 11.527
Authors: Jennifer T Huang; Carrie C Coughlin; Elena B Hawryluk; Kristen Hook; Stephen R Humphrey; Lacey Kruse; Leslie Lawley; Hasan Al-Sayegh; Wendy B London; Ashfaq Marghoob; Thuy L Phung; Elena Pope; Pedram Gerami; Birgitta Schmidt; Sarah Robinson; Diana Bartenstein; Eman Bahrani; Meera Brahmbhatt; Lily Chen; Ellen Haddock; Danny Mansour; Julie Nguyen; Tom Raisanen; Gary Tran; Kate Travis; Zachary Wolner; Lawrence F Eichenfield Journal: J Pediatr Date: 2019-05-15 Impact factor: 4.406
Authors: Arthur W Baker; Eileen K Maziarz; Christopher J Arnold; Melissa D Johnson; Adrienne D Workman; John M Reynolds; John R Perfect; Barbara D Alexander Journal: Clin Infect Dis Date: 2020-01-01 Impact factor: 9.079
Authors: Lawrence F Kuklinski; Shufeng Li; Margaret R Karagas; Wen-Kai Weng; Bernice Y Kwong Journal: J Am Acad Dermatol Date: 2017-08-02 Impact factor: 11.527